9031135064 - Oil Seal Sales results No. 1 Axle For Feb 34X63X10X22 Toyota Case $7 9031135064 - Oil Seal (Axle Case) (34X63X10X22) For Toyota - Feb Automotive Replacement Parts Oil,$7,Automotive , Replacement Parts,(Axle,Case),bodhispaetfitness.fr,/bibliofilm240166.html,Seal,9031135064,-,(34X63X10X22),-,Feb,Toyota,For 9031135064 - Oil Seal Sales results No. 1 Axle For Feb 34X63X10X22 Toyota Case $7 9031135064 - Oil Seal (Axle Case) (34X63X10X22) For Toyota - Feb Automotive Replacement Parts Oil,$7,Automotive , Replacement Parts,(Axle,Case),bodhispaetfitness.fr,/bibliofilm240166.html,Seal,9031135064,-,(34X63X10X22),-,Feb,Toyota,For

9031135064 - Oil Seal 100% quality warranty! Sales results No. 1 Axle For Feb 34X63X10X22 Toyota Case

9031135064 - Oil Seal (Axle Case) (34X63X10X22) For Toyota - Feb

$7

9031135064 - Oil Seal (Axle Case) (34X63X10X22) For Toyota - Feb

|||

Product description

This is a 90311 35064. The Febest Number is 95HBS-34631022L. This fits the following cars: TOYOTA MR-S ZZW30 1999-2002, TOYOTA MATRIX AZE14#/ZRE142 2008-, TOYOTA SCION XD ZSP110 2007-, TOYOTA AURIS/HYBRID (UKP) ADE15#/NDE150/NRE150/ZRE15#/ZZE150/ZWE150 20, TOYOTA AVENSIS ADT25#/AZT25#/CDT250/ZZT25# 2003-2008, TOYOTA COROLLA/ALTIS CE140/NDE140/NZE140/ZRE14#/ZZE14# 2007-, TOYOTA COROLLA/FIELDER CE121/NZE12#/ZZE12# 2000-2006, TOYOTA COROLLA/MATRIX (NAP) ZZE13# 2002-2008, TOYOTA COROLLA CE120/NZE12#/ZZE12# 2000-2008, TOYOTA CELICA ZZT23# 1999-2006, TOYOTA COROLLA AZE141/CE140/NZE141/ZRE14#/ZZE14# 2007-, TOYOTA COROLLA VERSO AUR10/CUR10/ZNR1# 2004-2009, TOYOTA COROLLA ADE150/NDE150/NRE150/ZRE15#/ZZE150 2006-. The compatible part numbers for this part are: 90311-35064, 0, 9031135058, , , 9031135064

9031135064 - Oil Seal (Axle Case) (34X63X10X22) For Toyota - Feb

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA